Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Aplidin
2. Aplidine
3. Dehydrodidemnin B
1. Aplidine
2. Aplidin
3. 137219-37-5
4. Dehydrodidemnin B
5. Y76id234hw
6. Chebi:90205
7. Plitidepsin (inn)
8. Plitidepsin [inn]
9. (2s)-n-[(2r)-1-[[(3s,6s,8s,12s,13r,16s,17r,20s,23s)-13-[(2s)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-n-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
10. Plitidepsin [inn:ban]
11. Plitidepsina
12. Plitidepsine
13. Plitidepsium
14. Unii-y76id234hw
15. Aplidine [mi]
16. Plitidepsin [mi]
17. Plitidepsin [mart.]
18. Plitidepsin [who-dd]
19. Didemnin A, N-(1-(1,2-dioxopropyl)-l-prolyl)-
20. Chembl451930
21. 2-9-didemnin B, 2-(1-(1,2-dioxopropyl)-l-proline)-
22. Schembl13413427
23. Gtpl11396
24. (s)-n-((r)-1-(((3s,6r,7s,10r,11s,15s,17s,20s,25as)-10-((s)-sec-butyl)-11-hydroxy-20-isobutyl-15-isopropyl-3-(4-methoxybenzyl)-2,6,17-trimethyl-1,4,8,13,16,18,21-heptaoxodocosahydro-15h-pyrrolo[2,1-f][1,15]dioxa[4,7,10,20]tetraazacyclotricosin-7-yl)amino)-4-methyl-1-oxopentan-2-yl)-n-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
25. At23636
26. Db04977
27. Hy-16050
28. Cs-0006129
29. D11032
30. Q4779975
31. Y-100032
32. (2s)-n-[(2r)-1-[[(3s,6s,8s,12s,13r,16s,17r,20s,23s)-13-[(2s)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl) Methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4-methyl-1-oxopentan-2-yl]-n-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
33. 1-(2-oxopropanoyl)-l-prolyl-n-[(3s,6r,7s,10r,11s,15s,17s,20s,25as)-10-[(2s)-butan-2-yl]-11-hydroxy-3-(4-methoxybenzyl)-2,6,17-trimethyl-20-(2-methylpropyl)-1,4,8,13,16,18,21-heptaoxo-15-(propan-2-yl)docosahydro-15h-pyrrolo[2,1-f][1,15,4,7,10,20]dioxatetraazacyclotricosin-7-yl]-n(2)-methyl-d-leucinamide
34. 3,6-anhydro(n-((2s,4s)-4-((3s,4r,5s)-3-hydroxy-4-((n-(2-oxopropanoyl)-l-prolyl-n-methyl-d-leucyl-l-threonyl)amino)-5-methylheptanoyloxy)-2,5-dimethyl-3-oxohexanoyl)-l-leucyl-l-prolyl-n,o-dimethyl-l-tyrosine)
35. L-tyrosine, 1-(1,2-dioxopropyl)-l-prolyl-n-methyl-d-leucyl-l-threonyl-(3s,4r,5s)-4-amino-3-hydroxy-5-methylheptanoyl-(2s,4s)-4-hydroxy-2,5-dimethyl-3-oxohexanoyl-l-leucyl-l-prolyl-n,o-dimethyl-, (8-3)-lactone
| Molecular Weight | 1110.3 g/mol |
|---|---|
| Molecular Formula | C57H87N7O15 |
| XLogP3 | 5.7 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 15 |
| Rotatable Bond Count | 15 |
| Exact Mass | 1109.62601509 g/mol |
| Monoisotopic Mass | 1109.62601509 g/mol |
| Topological Polar Surface Area | 285 Ų |
| Heavy Atom Count | 79 |
| Formal Charge | 0 |
| Complexity | 2200 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 12 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Intended for the treatment of various forms of cancer.
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XX - Other antineoplastic agents
L01XX57 - Plitidepsin
Hepatic
Aplidine inhibits the growth and induces apoptosis in MOLT-4 cells through the indirect inhibition of VEGF secretion which blocks the VEGF/VEGFR-1 autocrine loop necessary for the growth of these cells.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Plitidepsin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Plitidepsin, including repackagers and relabelers. The FDA regulates Plitidepsin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Plitidepsin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Plitidepsin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Plitidepsin supplier is an individual or a company that provides Plitidepsin active pharmaceutical ingredient (API) or Plitidepsin finished formulations upon request. The Plitidepsin suppliers may include Plitidepsin API manufacturers, exporters, distributors and traders.
click here to find a list of Plitidepsin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Plitidepsin DMF (Drug Master File) is a document detailing the whole manufacturing process of Plitidepsin active pharmaceutical ingredient (API) in detail. Different forms of Plitidepsin DMFs exist exist since differing nations have different regulations, such as Plitidepsin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Plitidepsin DMF submitted to regulatory agencies in the US is known as a USDMF. Plitidepsin USDMF includes data on Plitidepsin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Plitidepsin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Plitidepsin suppliers with USDMF on PharmaCompass.
Plitidepsin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Plitidepsin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Plitidepsin GMP manufacturer or Plitidepsin GMP API supplier for your needs.
A Plitidepsin CoA (Certificate of Analysis) is a formal document that attests to Plitidepsin's compliance with Plitidepsin specifications and serves as a tool for batch-level quality control.
Plitidepsin CoA mostly includes findings from lab analyses of a specific batch. For each Plitidepsin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Plitidepsin may be tested according to a variety of international standards, such as European Pharmacopoeia (Plitidepsin EP), Plitidepsin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Plitidepsin USP).
LOOKING FOR A SUPPLIER?
